Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | LTA4H | P09960 | 2/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | AKT1 | P31749 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1052780 | 0.87 | HDAC3 (0.53) | HDAC3HDAC1HDAC2NCOR2SMN1; SMN2 | |
| SCHEMBL5884593 | 0.87 | HDAC1 (0.53) | HDAC3HDAC1HDAC2NCOR2ALDH1A1 | |
| SCHEMBL3914953 | 0.85 | ALOX5 (0.46) | HDAC3HDAC1HDAC2NCOR2ALOX5 | |
| SCHEMBL4147838 | 0.85 | HDAC1 (0.56) | HDAC3HDAC1HDAC2NCOR2ALDH1A1 | |
| SCHEMBL9060170 | 0.84 | HDAC1 (0.60) | HDAC3HDAC1HDAC2NCOR2ALDH1A1 | |
| SCHEMBL17686967 | 0.82 | SLC6A2 (0.48) | SMN1; SMN2ALDH1A1LMNAPOLB | |
| SCHEMBL20347975 | 0.81 | REN (0.58) | HDAC3HDAC1HDAC2ALOX5SMN1; SMN2 | |
| SCHEMBL2224578 | 0.81 | SMN1; SMN2 (0.54) | ALOX5SMN1; SMN2ALDH1A1LTA4HLMNA | |
| SCHEMBL11728356 | 0.81 | ALOX5 (0.48) | ALOX5SMN1; SMN2ALDH1A1LTA4HLMNA | |
| SCHEMBL3328177 | 0.81 | HDAC3 (0.54) | HDAC3HDAC1HDAC2NCOR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090182010-A1 | COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-07-16 | — | — | US | disclosed |
| US-7528253-B2 | Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity | THERAVANCE, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20090062342-A1 | AMINES | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-03-05 | — | — | US | disclosed |
| US-20060116398-A1 | Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity | THERAVANCE BIOPHARMA R&D IP, LLC | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182010-A1 | COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | ADRB2, ADRA2B, ADRA2A | HDAC3 1584/4885HDAC1 1705/4885HDAC2 1119/4885 |
| US-20090062342-A1 | AMINES | REN, ACE, MAOA | HDAC3 3308/4885HDAC1 2808/4885HDAC2 1943/4885 |
| US-20060116398-A1 | Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity | ADRB2, ADRA2B, ADRB1 | HDAC3 1648/4885HDAC1 1770/4885HDAC2 1161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.